R&D Does the answer to advancing rare disease treatment lie in r... What do 300 million people have in common? They are living with rare diseases that are defined by their scarcity within the general population.
News Quartet of biotechs join Nasdaq after stellar IPOs Braveheart Bio, Latigo Biotherapeutics, Attovia Therapeutics, and BlossomHill Therapeutics have finalised their Nasdaq listings, raising over $1.2bn.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.